Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer

Cancer
Sean KhozinAmy P Abernethy

Abstract

Despite the rapid adoption of immunotherapies in advanced non-small cell lung cancer (advNSCLC), knowledge gaps remain about their real-world (rw) performance. This retrospective, observational, multicenter analysis used the Flatiron Health deidentified electronic health record-derived database of rw patients with advNSCLC who received treatment with PD-1 and/or PD-L1 (PD-[L]1) inhibitors before July 1, 2017 (N = 5257) and had ≥6 months of follow-up. The authors investigated PD-(L)1 line of treatment and PD-L1 testing rates and the relationship between overall survival (OS) and rw intermediate endpoints: progression-free survival (rwPFS), rw time to progression (rwTTP), rw time to next treatment (rwTTNT), and rw time to discontinuation (rwTTD). First-line PD-(L)1 inhibitor use increased from 0% (in the third quarter of 2014 [Q3 2014]) to 42% (Q2 2017) over the study period. PD-L1 testing also increased (from 3% in Q3 2015 to 70% in Q2 2017). The estimated median OS was 9.3 months (95% CI, 8.9-9.8 months), and the estimated rwPFS was 3.2 months (95% CI, 3.1-3.3 months). Longer OS and rwPFS were associated with ≥50% PD-L1 percentage staining results. Correlations (⍴) between OS and intermediate endpoints were ⍴ = 0.75 (95% CI, 0....Continue Reading

References

Nov 4, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sumithra J MandrekarAlex A Adjei
Nov 21, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Katsuyuki HottaKatsuyuki Kiura
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jun 23, 2016·Applied Immunohistochemistry & Molecular Morphology : AIMM·Charlotte RoachKarina Kulangara
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Dec 14, 2016·The New England Journal of Medicine·Rachel E ShermanRobert M Califf
Apr 13, 2017·Expert Review of Anticancer Therapy·Frédéric FiteniFranck Bonnetain
Jul 27, 2017·Journal of Oncology Practice·Amy P AbernethyCindy Revol
Oct 24, 2017·Journal of the National Cancer Institute·Sean KhozinRichard Pazdur
Dec 10, 2017·Journal of Thoracic Disease·Xiuning LeDaniel B Costa
May 15, 2018·Health Services Research·Melissa D CurtisAmy P Abernethy

❮ Previous
Next ❯

Citations

Jun 2, 2020·JCO Clinical Cancer Informatics·Gabrielle B RocqueAndres Azuero
Mar 27, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monica M BertagnolliSean Khozin
Oct 20, 2020·JCO Clinical Cancer Informatics·Jennifer LaNathanael R Fillmore
Oct 24, 2020·Journal of Comparative Effectiveness Research·Sreeram V RamagopalanCormac Sammon
Apr 15, 2020·Cancer Cell·Yonina R Murciano-GoroffAlison M Schram
Feb 5, 2021·Journal of Clinical Medicine·Alberto Caballero-VázquezGuillermo Arturo Cañadas-De la Fuente
Apr 25, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·David WaterhouseDavid Stenehjem
May 14, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Didier DebieuvreMartin Sebastian
Jun 2, 2021·American Society of Clinical Oncology Educational Book·Nikhil I KhushalaniJohn F Thompson
Jul 7, 2021·Pharmacoepidemiology and Drug Safety·Blythe J S AdamsonAriel B Bourla
Aug 3, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Anita AndreanoAntonio Giampiero Russo
Jul 25, 2021·International Journal of Environmental Research and Public Health·Andrea SpiniGiuseppe Roberto
Aug 28, 2021·Statistical Methods in Medical Research·Jie ZhouBrian P Hobbs
Sep 15, 2021·Journal of Comparative Effectiveness Research·Ashley Jaksa, Nirosha Mahendraratnam
Oct 17, 2021·Clinical Pharmacology and Therapeutics·Laura LasiterJeff Allen

❮ Previous
Next ❯

Software Mentioned

R
CTCAE
R Foundation for Statistical Computing

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.